Literature DB >> 26880408

Prostate Cancer Diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling.

Raju Chelluri1, Amichai Kilchevsky1, Arvin K George1, Abhinav Sidana1, Thomas P Frye1, Daniel Su1, Michele Fascelli1, Richard Ho1, Steven F Abboud1, Baris Turkbey2, Maria J Merino3, Peter L Choyke2, Bradford J Wood4, Peter A Pinto5.   

Abstract

PURPOSE: Urologists face a dilemma when a lesion identified on multiparametric magnetic resonance imaging is benign on image guided fusion biopsy. We investigated the detection rate of prostate cancer on repeat fusion biopsy in multiparametric magnetic resonance imaging lesions initially found to be pathologically benign on fusion biopsy.
MATERIALS AND METHODS: We reviewed the records of all patients from 2007 to 2014 who underwent multiparametric magnetic resonance imaging and image guided fusion biopsy. We identified men who underwent rebiopsy of the same discrete lesion after initial fusion biopsy results were benign. Data were documented on a per lesion basis. We manually reviewed UroNav system (Invivo, Gainesville, Florida) needle tracking to verify accurate image registration. Multivariate analysis was used to identify clinical and imaging factors predictive of prostate cancer detection at repeat fusion biopsy.
RESULTS: A total of 131 unique lesions were rebiopsied in 90 patients. Of these 131 resampled lesions 21 (16%) showed prostate cancer, which in 13 (61.9%) was Gleason 3 + 3. On multivariate analysis only lesion growth on repeat multiparametric magnetic resonance imaging was significantly associated with prostate cancer detection at repeat biopsy (HR 3.274, 95% CI 1.205-8.896, p = 0.02).
CONCLUSIONS: Pathologically benign multiparametric magnetic resonance imaging lesions on initial image guided fusion biopsy are rarely found to harbor clinically significant prostate cancer on repeat biopsy. When prostate cancer was identified, most disease was low risk. An increase in lesion diameter was an independent predictor of prostate cancer detection. While these data are retrospective, they may provide some confidence in the reliability of negative initial image guided fusion biopsies despite a positive multiparametric magnetic resonance imaging finding.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  high-intensity focused; image-guided biopsy; magnetic resonance imaging; prostatic neoplasms; transrectal; ultrasound; watchful waiting

Mesh:

Year:  2016        PMID: 26880408      PMCID: PMC7830711          DOI: 10.1016/j.juro.2016.02.066

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

Review 1.  Optimizing Patient Population for MP-MRI and Fusion Biopsy for Prostate Cancer Detection.

Authors:  Thomas P Frye; Peter A Pinto; Arvin K George
Journal:  Curr Urol Rep       Date:  2015-07       Impact factor: 3.092

2.  Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session.

Authors:  Cheng William Hong; Annerleim Walton-Diaz; Soroush Rais-Bahrami; Anthony N Hoang; Barış Türkbey; Lambros Stamatakis; Sheng Xu; Hayet Amalou; M Minhaj Siddiqui; Jeffrey W Nix; Srinivas Vourganti; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

3.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

4.  Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.

Authors:  A A Hussein; C J Welty; N Ameli; J E Cowan; M Leapman; S P Porten; K Shinohara; P R Carroll
Journal:  J Urol       Date:  2015-01-23       Impact factor: 7.450

5.  Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy.

Authors:  Ardeshir R Rastinehad; Baris Turkbey; Simpa S Salami; Oksana Yaskiv; Arvin K George; Mathew Fakhoury; Karin Beecher; Manish A Vira; Louis R Kavoussi; David N Siegel; Robert Villani; Eran Ben-Levi
Journal:  J Urol       Date:  2013-12-12       Impact factor: 7.450

6.  Comparison of magnetic resonance imaging and ultrasound (MRI-US) fusion-guided prostate biopsies obtained from axial and sagittal approaches.

Authors:  Cheng W Hong; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Nabeel Shakir; Daniel Su; Arvin K George; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  BJU Int       Date:  2014-12-15       Impact factor: 5.588

7.  Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology.

Authors:  Jesse D Le; Samuel Stephenson; Michelle Brugger; David Y Lu; Patricia Lieu; Geoffrey A Sonn; Shyam Natarajan; Frederick J Dorey; Jiaoti Huang; Daniel J A Margolis; Robert E Reiter; Leonard S Marks
Journal:  J Urol       Date:  2014-05-01       Impact factor: 7.450

8.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.

Authors:  Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood
Journal:  J Urol       Date:  2011-08-17       Impact factor: 7.450

9.  Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

Authors:  Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2015-06-18       Impact factor: 11.105

10.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

View more
  12 in total

Review 1.  Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.

Authors:  Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto
Journal:  Future Oncol       Date:  2016-07-12       Impact factor: 3.404

2.  Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy.

Authors:  Akhil Muthigi; Arvin K George; Abhinav Sidana; Michael Kongnyuy; Richard Simon; Vanessa Moreno; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2016-08-28       Impact factor: 7.450

Review 3.  Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning.

Authors:  Steven Sidelsky; Shaan Setia; Srinivas Vourganti
Journal:  Curr Urol Rep       Date:  2017-10-18       Impact factor: 3.092

4.  Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.

Authors:  Akhil Muthigi; Abhinav Sidana; Arvin K George; Michael Kongnyuy; Nabeel Shakir; Meet Kadakia; Mahir Maruf; Thomas P Frye; Francesca Mertan; Daniel Su; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  Int Urol Nephrol       Date:  2016-06-15       Impact factor: 2.370

5.  An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.

Authors:  Daniel N Costa; Fernando U Kay; Ivan Pedrosa; Lauren Kolski; Yair Lotan; Claus G Roehrborn; Brad Hornberger; Yin Xi; Franto Francis; Neil M Rofsky
Journal:  Urol Oncol       Date:  2016-12-09       Impact factor: 3.498

6.  Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.

Authors:  Edward Chang; Tonye A Jones; Shyam Natarajan; Devi Sharma; Demetrios Simopoulos; Daniel J Margolis; Jiaoti Huang; Frederick J Dorey; Leonard S Marks
Journal:  J Urol       Date:  2017-07-18       Impact factor: 7.450

7.  A urologist's perspective on prostate cancer imaging: past, present, and future.

Authors:  Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto
Journal:  Abdom Radiol (NY)       Date:  2016-05

8.  Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.

Authors:  Thomas P Frye; Arvin K George; Amichai Kilchevsky; Mahir Maruf; M Minhaj Siddiqui; Michael Kongnyuy; Akhil Muthigi; Hui Han; Howard L Parnes; Maria Merino; Peter L Choyke; Baris Turkbey; Brad Wood; Peter A Pinto
Journal:  J Urol       Date:  2016-09-06       Impact factor: 7.450

Review 9.  A critical comparison of techniques for MRI-targeted biopsy of the prostate.

Authors:  Francesco Giganti; Caroline M Moore
Journal:  Transl Androl Urol       Date:  2017-06

10.  Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB.

Authors:  Wulphert Venderink; Sjoerd Fm Jenniskens; J P Michiel Sedelaar; Tsutomu Tamada; Jurgen J Fütterer
Journal:  Korean J Radiol       Date:  2018-06-14       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.